Last reviewed 2026-04-20 · How we verify

Hippuran I125 (iodohippurate sodium I125)

Hippuran I125 (generic name: iodohippurate sodium I125) is a iodohippurate sodium I125 drug. It is currently in unknown development.

Hippuran I125 works by binding to and being excreted by the kidneys, allowing for imaging of renal function.

Hippuran I125 (iodohippurate sodium I125) is a small molecule radiopharmaceutical in the iodohippurate sodium I125 drug class. Its exact target and mechanism of action are unknown, but it is used for diagnostic purposes. The commercial status of Hippuran I125 is unclear, and it may be patented or off-patent. Key safety considerations include the use of radioactive iodine, which requires proper handling and disposal. Further information on its approved indications, half-life, and bioavailability is not available.

At a glance

Mechanism of action

Imagine your kidneys as filters that clean your blood. Hippuran I125 is a small molecule that gets filtered out by the kidneys and then excreted into the urine. By tracing the path of this molecule, doctors can see how well the kidneys are working.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Hippuran I125 CI brief — competitive landscape report
• Hippuran I125 updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Hippuran I125

Related

• Drug class: All iodohippurate sodium I125 drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing